Drug Profile
Insulin long-acting (HM 12470) - Hanmi Pharmaceutical
Alternative Names: LAPSInsulin / LAPSInsulin Analog; LAPSInsulin 115; HM 12470; HM-12470A; HM12460A / HM12470; HM12460A / LAPS-Insulin115; LAPS-Insulin; SAR 440067Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in South Korea (SC, Injection)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC, Injection)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in South Korea (SC, Injection)